Depo-Provera Meningioma Lawsuit in District of Columbia
Last Updated: April 1, 2026
The District of Columbia's three-year statute of limitations for both personal injury and product liability claims gives residents additional time to pursue Depo-Provera and GLP-1 medication injury cases. As the nation's capital, D.C. is home to federal regulatory agencies including the FDA, and its courts are familiar with pharmaceutical regulatory issues. The District's concentrated urban population and extensive medical infrastructure mean many residents have been prescribed these medications through local health systems.
Depo-Provera (medroxyprogesterone acetate) has been linked to meningioma brain tumors. The FDA added a black-box warning in December 2025, and over 3,000 lawsuits have been filed nationwide. District of Columbia residents who used Depo-Provera and were diagnosed with a meningioma may qualify for compensation. The statute of limitations in District of Columbia for personal injury claims is 3 years. Attorneys handle these cases on a contingency fee basis — no cost unless you win.
Depo-Provera Meningioma Claims in District of Columbia
Depo-Provera (medroxyprogesterone acetate) has been linked to meningioma brain tumors. The FDA added a black-box warning in December 2025, and over 3,000 lawsuits have been filed nationwide. District of Columbia residents who used Depo-Provera and were diagnosed with a meningioma may qualify for compensation on a contingency fee basis — no cost unless you win.
In December 2025, the FDA took the significant step of updating Depo-Provera's label to include a formal warning about the elevated risk of meningioma associated with prolonged use. This label change came after years of accumulating scientific evidence — including studies from France and other countries — demonstrating a clear dose-response relationship between medroxyprogesterone acetate and meningioma development.
For District of Columbia residents who used Depo-Provera and were subsequently diagnosed with a meningioma, the legal landscape is now clear: the manufacturer knew or should have known about this risk and failed to provide adequate warnings. Over 3,000 lawsuits have been filed across the country, and District of Columbia residents are actively filing claims to seek compensation for their injuries.
Meningiomas, while often classified as benign tumors, can cause devastating symptoms including chronic headaches, seizures, vision and hearing problems, cognitive impairment, and personality changes. Treatment frequently requires invasive brain surgery, radiation therapy, or both. Many patients face recurring tumors and lifelong monitoring.
District of Columbia legal landscape: D.C. applies strict liability for defective products under Restatement (Second) of Torts Section 402A and follows a contributory negligence standard — one of the few jurisdictions where any plaintiff fault can completely bar recovery. Residents in Washington and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.
District of Columbia Statute of Limitations
Understanding the statute of limitations is critical for District of Columbia residents considering a Depo-Provera meningioma lawsuit. In District of Columbia, the statute of limitations for personal injury claims is 3 years. For product liability claims specifically, the deadline is 3 years.
District of Columbia recognizes the discovery rule, which is particularly important in pharmaceutical injury cases. Under this rule, the statute of limitations may begin running not from the date of your last Depo-Provera injection, but from the date you discovered — or reasonably should have discovered — the connection between Depo-Provera and your meningioma. Given that the FDA only formally warned about this risk in December 2025, many District of Columbia residents may still be within their filing window even if their diagnosis occurred years ago.
Do not assume your deadline has passed without consulting an attorney. The interplay between personal injury and product liability statutes, the discovery rule, and the facts of your specific case can create nuances that only a qualified legal professional can properly evaluate.
Personal Injury SOL
3 years
Product Liability SOL
3 years
Discovery Rule
Yes
How to File a Depo-Provera Lawsuit in District of Columbia
Filing a Depo-Provera meningioma lawsuit in District of Columbia involves several steps, but the process begins with a simple, no-cost case evaluation. Here is what to expect:
Free Case Review
Complete a free case evaluation to determine whether your Depo-Provera usage and meningioma diagnosis qualify for legal action under District of Columbia law.
Attorney Referral
If your case qualifies, you will be connected with experienced mass tort attorneys licensed to practice in District of Columbia who specialize in pharmaceutical litigation.
Case Filing
Your attorney will file your claim in the appropriate court. In District of Columbia, cases may be filed in the D.C. Superior Court or in federal court (United States District Court for the District of Columbia).
Litigation & Resolution
Your legal team handles all proceedings including discovery, depositions, and trial preparation. You pay nothing unless you receive compensation through settlement or verdict.
Do You Qualify in District of Columbia?
District of Columbia residents may be eligible to file a Depo-Provera meningioma claim if the following criteria are met:
Used Depo-Provera Injections
You received one or more Depo-Provera (medroxyprogesterone acetate) injections while residing in District of Columbia or another state.
Diagnosed with a Meningioma
You have been diagnosed with a meningioma brain tumor, confirmed through imaging (MRI or CT scan) or surgical pathology.
Timeline Consistent with Causation
Your meningioma diagnosis occurred after you began receiving Depo-Provera injections, establishing a timeline that supports a causal connection.
Within the Filing Deadline
Your claim falls within District of Columbia's statute of limitations (3 years for personal injury). The discovery rule may extend this deadline — an attorney can evaluate your specific timeline.
District of Columbia Depo-Provera FAQ
What is a meningioma and how is it linked to Depo-Provera in District of Columbia?
A meningioma is a tumor that forms on the membranes covering the brain and spinal cord. In December 2025, the FDA updated Depo-Provera's label to warn about the increased risk of meningioma brain tumors. District of Columbia residents who used Depo-Provera and were later diagnosed with a meningioma may be eligible to file a claim. Multiple studies have shown that prolonged use of medroxyprogesterone acetate, the active ingredient in Depo-Provera, is associated with a significantly elevated risk of developing meningiomas.
What is the statute of limitations for a Depo-Provera lawsuit in District of Columbia?
In District of Columbia, the statute of limitations for personal injury claims is 3 years from the date of injury or discovery. District of Columbia recognizes the discovery rule, which means the clock may start when you discovered — or reasonably should have discovered — the connection between Depo-Provera and your meningioma, rather than the date of your last injection. Because these deadlines are strict and missing them can permanently bar your claim, prompt action is critical.
How do I file a Depo-Provera meningioma lawsuit in District of Columbia?
Filing a Depo-Provera meningioma lawsuit in District of Columbia begins with a free case review to determine your eligibility. If your case qualifies, you will be connected with experienced mass tort attorneys who can file your claim in either the D.C. Superior Court or the appropriate federal district court. Most cases are being consolidated in federal multidistrict litigation (MDL) for efficiency. Your attorney handles all legal filings and proceedings on your behalf.
What compensation is available for District of Columbia Depo-Provera victims?
District of Columbia residents who qualify may be entitled to compensation for medical expenses (surgery, radiation, imaging, hospital stays, and ongoing monitoring), lost wages and diminished earning capacity, pain and suffering, and emotional distress. The amount of compensation depends on the severity of your meningioma, the treatment required, and the impact on your daily life and ability to work.
Which courts handle Depo-Provera cases in District of Columbia?
Depo-Provera meningioma cases in District of Columbia can be filed in the D.C. Superior Court at the state level or in federal court. The federal districts covering District of Columbia include the United States District Court for the District of Columbia. Many cases are being consolidated in a federal multidistrict litigation (MDL) for pretrial proceedings, with individual cases returning to their home districts for trial if needed.
Does it cost anything to file a Depo-Provera claim in District of Columbia?
There is no upfront cost to file a Depo-Provera meningioma claim in District of Columbia. Attorneys handling these cases work on a contingency fee basis, meaning they only receive payment if you obtain compensation through a settlement or trial verdict. NuLegal's initial case review is completely free with no obligation to proceed.
Related Resources
District of Columbia Residents: Don't Wait
The statute of limitations in District of Columbia is 3 years for personal injury claims. Get a free, no-obligation case review today to find out if you qualify for compensation.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.